Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
Joint Authors
Suarez-De-Figueroa, Marta
García-Layana, Alfredo
Gallego-Pinazo, Roberto
García-Campos, José Manuel
Araiz, Javier
Ruiz-Moreno, José María
García-Arumí, José
López-Gálvez, María Isabel
Cabrera-López, Francisco
Monés, Jordi
Cervera, Enrique
Armadá, Felix
Gómez-Ulla, Francisco
Arias, L.
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-09-27
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration.
Intravitreal anti-VEGF drugs are the current gold standard.
Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials.
A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity.
Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss.
Several trials suggest that “treat and extend” and other proactive regimens provide a reasonable approach.
The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drops in vision while individualizing patient followup.
Treat and extend study results in significant direct medical cost savings from fewer treatments and office visits compared to monthly treatment.
Current data suggest that, for one year, PRN is less expensive, but treat and extend regimen would likely be less expensive for subsequent years.
Once a patient is not a candidate to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD patients in order to reduce the burden of specialized ophthalmologist services.
American Psychological Association (APA)
García-Layana, Alfredo& Suarez-De-Figueroa, Marta& Arias, L.& Araiz, Javier& Ruiz-Moreno, José María& García-Arumí, José…[et al.]. 2015. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. Journal of Ophthalmology،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1069729
Modern Language Association (MLA)
García-Layana, Alfredo…[et al.]. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. Journal of Ophthalmology No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1069729
American Medical Association (AMA)
García-Layana, Alfredo& Suarez-De-Figueroa, Marta& Arias, L.& Araiz, Javier& Ruiz-Moreno, José María& García-Arumí, José…[et al.]. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. Journal of Ophthalmology. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1069729
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1069729